Biogen Inc. (NASDAQ: BIIB): Oppenheimer raised its $300 target price on the biotech giant to $315 while maintaining an Outperform rating. The consensus target is $300.89. Monday’s close at $299.06 was up over 3% for the day.
Chart Industries Inc. (NYSE: GTLS): Wells Fargo’s downgraded to Equal Weight from Overweight included a target price cut to $148 from $248. The consensus target is $233.56 for now. The stock closed over 6% lower on Monday at $131. The company is buying Howden for $4.4 billion and also posted earnings that missed expectations last week.
CyberArk Software Ltd. (NASDAQ: CYBR): Stifel reiterated a Buy rating with a $183 target price. The consensus target is $180.54. The stock closed on Monday at $157.38.
EPAM Systems Inc. (NYSE: EPAM): Jefferies reiterated a Buy rating with a $535 target price. The consensus target is just $418.75. The last trade on Monday was reported at $358.10.
Essex Property Trust Inc. (NYSE: ESS): As BofA Securities lowered its Buy rating to Neutral, it also dropped its $265 target price to $233. The consensus target is $266.50. The shares ended Monday trading at $210.47.
Global Payments Inc. (NYSE: GPN): Baird downgraded the stock to Neutral from Outperform. It also slashed its $144 target price to $118. The consensus target is $150.75 for now. The last trade for Monday was reported at $103.23.
Jack in the Box Inc. (NASDAQ: JACK): Oppenheimer reiterated an Outperform rating on the fast-food favorite and has a $107 target price. The consensus target is $91.78. The stock closed on Monday at $84.75.
Kanzhun Ltd. (NASDAQ: BZ): Goldman Sachs upgraded the stock to Buy from Neutral but cut its $27.50 target price to $23, below the consensus target of $26.99. Monday’s $16.09 close was up almost 6% for the day on the potential for Chinese lockdowns to be curtailed.
Medical Properties Trust (NYSE: MPW): BofA Securities raised its Neutral rating to Buy and bumped its $13 price target up to $16. The consensus target for the REIT is $16.46. Monday’s close was at $12.48.
Meta Platforms Inc. (NASDAQ: META): Oppenheimer raised its $140 target price on the Facebook and Instagram parent to $145 while reiterating an Outperform rating. The consensus target is $154.89. final Monday’s close was at $114.22.
Neurocrine Biosciences Inc. (NASDAQ: NBIX): Evercore ISI downgraded the stock to In line from Outperform. The analyst also cut the $140 target price to $130, still above the $128.00 consensus target. The final Monday trade was reported at $118.05.
Nvidia Inc. (NASDAQ: NVDA): Stifel maintained a Hold rating with a $165 target price. The consensus target is up at $189.37. The shares closed on Monday at $162.95
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
